Melanoma News and Research

Latest Melanoma News and Research

World's first treatment of metastasized brain cancer uses IsoRay's Cesium-131 brachytherapy seeds

IsoRay, a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, announced today that doctors at New York Presbyterian Hospital/ Weill Cornell Medical Center have performed the world's first treatment of metastasized brain cancer using IsoRay's Cesium-131 brachytherapy seeds.

26 Sep 2011

Percutaneous hepatic perfusion extends survival time for melanoma patients

Melanoma of the eye frequently spreads to the liver and, once this has happened, there is no effective treatment and patients die within an average of two to four months. Only about one in ten patients live for a year. Now, final results from a phase III study have demonstrated that a new treatment significantly extends the time patients can live without the disease progressing.

26 Sep 2011

Adeno-associated virus type 2 kills human breast cancer cells in lab

A nondisease-causing virus kills human breast cancer cells in the laboratory, creating opportunities for potential new cancer therapies, according to Penn State College of Medicine researchers who tested the virus on three different breast cancer types that represent the multiple stages of breast cancer development.

23 Sep 2011

Ono, Bristol-Myers Squibb partner to develop BMS-936558/ONO-4538 and ORENCIA

Bristol-Myers Squibb Company and Ono Pharmaceutical Co., Ltd., today announced an agreement to expand Bristol-Myers Squibb's territorial rights to develop and commercialize the anti-PD-1 antibody known as BMS-936558/ONO-4538, and to create a strategic alliance for the co-development and co-commercialization of ORENCIA in Japan.

21 Sep 2011

Beta-blocker drugs may improve survival time for melanoma patients

Beta-blocker drugs, commonly used to treat high blood pressure, may also play a major role in slowing the progression of certain serious cancers, based on a new study.

21 Sep 2011

Preclinical studies shows EmPAC more effective than Taxol

Cornerstone Pharmaceuticals, Inc. has announced the publication of data from preclinical studies on EmPAC™, its nanoparticle reformulation of paclitaxel, in the August issue of the Journal of Nanoscience and Nanotechnology. The publication highlights data demonstrating improved safety and efficacy of EmPAC™ versus Taxol®, the generic formulation of paclitaxel and one of the most widely prescribed chemotherapies. EmPAC™ is a nanoemulsion formulation of Paclitaxel and is the lead product candidate of Cornerstone’s proprietary Emulsiphan™ cancer selective delivery nanotechnology platform. Taxol®, an injectable formulation of Paclitaxel, is currently used to treat a variety of cancers, including ovarian carcinomas, breast cancer, non-small cell lung cancer, and AIDS-related Kaposi’s sarcoma.

19 Sep 2011

Revolution in drug discovery underway in West Midlands, UK

A revolution in the drug discovery industry is underway, with universities across the West Midlands leading the effort by working in partnership with industry to focus on improving patient care.

19 Sep 2011

Top-line data from Spectrum's SPI-1620 Phase 1 combination study on carcinoma

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that top-line data from part one of a two-part Phase 1 study of SPI-1620 in combination with docetaxel was presented in an oral presentation at the 12th International Conference on Endothelin, held in Cambridge, United Kingdom, from September 11-14, 2011. Part one of the study has been completed, while part two is ongoing.

19 Sep 2011

Vesicular stomatitis virus kills cancer cells

In a new project, researchers from LIFE - the Faculty of Life Sciences at the University of Copenhagen - document that the vesicular stomatitis virus (VSV) plays a previously unknown dual role in the prevention of a number of cancers. The new findings show that the virus both kills cancer cells and stops the expression of the molecules which certain types of cancer cells produce to hide from the immune system.

17 Sep 2011

Rac1 protein triggers growth of long 'legs' that could propel melanoma cells to spread

Cancer Research UK scientists have discovered that a protein called Rac1 prompts pigment cells to sprout long 'legs' that could propel skin cancer cells, allowing them to spread, according to research published in Developmental Cell today.

15 Sep 2011

Delcath announces updated Phase 2 trial results from metastatic neuroendocrine tumor cohort

Delcath Systems, Inc. announced that updated results from the metastatic neuroendocrine tumor (mNET) cohort of the Company's recently completed Phase 2 clinical trial were presented at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) congress held this week in Munich, Germany.

13 Sep 2011

IsoRay receives FDA clearance for GliaSite radiation therapy system to treat brain cancer

IsoRay, Inc. announced today that the FDA has cleared its GliaSite radiation therapy system, a balloon catheter device used in the treatment of brain cancer.

12 Sep 2011

LC-MRM could provide better understanding of multiple myeloma drug resistance

12 Sep 2011

Moffitt researchers employ LC-MRM to detect acquired multiple myeloma drug resistance

"Acquired drug resistance" (ADR) is a major problem encountered in treating some forms of cancer. The ability to monitor the proteins involved in drug resistance has been a hurdle facing cancer researchers. However, a team of researchers at Moffitt Cancer Center, and colleagues, are pioneering promising research utilizing a monitoring technology that could provide a better understanding of ADR and assist in clinical decision-making for developing individualized patient treatments for multiple myeloma.

9 Sep 2011

Aura's NanoSmart platform can enable earlier detection, treatment of cancers

Aura Biosciences, Inc., a biotech company focused on the development of nano-enabled drug delivery systems, has completed several pre-clinical research programs. The resulting data suggest that Aura's NanoSmart platform can enable earlier detection of cancers and distant metastases; and then provide precisely targeted treatment of those cancers.

9 Sep 2011

New guidelines for treatment of melanoma

Based on an extensive review of scientific literature and the recommendations of recognized melanoma experts, the American Academy of Dermatology (Academy) has released updated evidence-based guidelines for the treatment of melanoma, the deadliest form of skin cancer.

8 Sep 2011

BioAlliance Pharma announces oral communication of Livatag Phase II trial results on liver cancer

BioAlliance Pharma SA, a company dedicated to specialty and orphan oncology products, today announces oral communication of the Phase II clinical trial results of its orphan product Livatag at the annual congress of ILCA, the only international organization devoted exclusively to liver cancer research with participation of worldwide best specialists.

6 Sep 2011

CRI announces winners of 2011 Coley Award for distinguished research in tumor immunology

The Cancer Research Institute, Inc. (CRI), a U.S. nonprofit organization established in 1953 to advance the science of tumor immunology and drive the discovery of new cancer immunotherapies, announced today the winners of the 2011 William B. Coley Award for Distinguished Research in Tumor Immunology.

2 Sep 2011

Sunscreen pills from coral

Researchers have found that coral does not suffer from sunburn despite living in shallow water in tropical areas, because it is able to produce its own “natural sunscreen”. By studying the compounds which protect it from UV rays, researchers hope to develop a tablet which can protect human skin and eyes without the need for dark glasses or sun cream. Scientists from King's College London said the first sunscreen pill could be available within five years.

31 Aug 2011

Patients with sarcopenia more likely to have worse outcomes from melanoma

It's not how old but how frail patients are that can predict how well they will fare after a melanoma diagnosis. In fact, young patients in poor health may have worse outcomes than older patients in good shape.

31 Aug 2011